Covered recipient · General Payments record
JANICE FENG
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Adult Health
General Payments · PY2023–2025
$2,795.90
- Reported across 77 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $368.55 | 15 |
| Education | $95.00 | 1 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $98.70 | 4 |
| SEAGEN INC. | $95.00 | 1 |
| Merck Sharp & Dohme Corporation | $75.55 | 3 |
| EISAI INC. | $58.38 | 2 |
| Acerta Pharma LLC | $46.96 | 2 |
| PROGENICS PHARMACEUTICALS, INC. | $30.26 | 1 |
| Janssen Biotech, Inc. | $26.60 | 1 |
| Telix Pharmaceuticals | $17.05 | 1 |
| Astellas Pharma US Inc | $15.05 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Astellas Pharma US Inc | $15.05 | 05/30/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238798745 | CMS |
| AstraZeneca Pharmaceuticals LP | $26.53 | 07/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1206816018 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.43 | 10/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1207018192 | CMS |
| Eisai Inc. | $34.20 | 07/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1244533977 | CMS |
| Eisai Inc. | $24.18 | 10/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1244533979 | CMS |
| Janssen Biotech, Inc. | $26.60 | 10/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1175434676 | CMS |
| Merck Sharp & Dohme LLC | $19.63 | 06/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238078169 | CMS |
| Merck Sharp & Dohme LLC | $30.58 | 07/30/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238259391 | CMS |
| Merck Sharp & Dohme LLC | $25.34 | 12/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238263372 | CMS |
| PFIZER INC. | $24.61 | 07/22/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1230519777 | CMS |
| PFIZER INC. | $24.07 | 07/24/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1230557487 | CMS |
| PFIZER INC. | $24.88 | 09/26/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1230598485 | CMS |
| PFIZER INC. | $25.14 | 11/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1230988753 | CMS |
| PROGENICS PHARMACEUTICALS, INC. | $30.26 | 10/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1245224830 | CMS |
| SEAGEN INC. | $95.00 | 07/15/2025 | Education | Undisputed | 06/30/2026 | 1230513386 | CMS |
| Telix Pharmaceuticals | $17.05 | 09/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1189640019 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.